Oritavancin Diphosphate Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 400 mg

Reference Brands: Orbactiv (USA)

Category: Antibiotics

Oritavancin Diphosphate is available in Injection and strengths such as 400 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Oritavancin Diphosphate is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Oritavancin Diphosphate can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Oritavancin, marketed under the brand name Orbactiv, is a semisynthetic glycopeptide antibiotic used for the treatment of serious Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). Structurally related to vancomycin, it is a lipoglycopeptide that inhibits bacterial cell wall synthesis and disrupts membrane integrity, leading to rapid bacterial cell death.

Oritavancin is considered a long-acting antibiotic due to its extended half-life of up to 16 days and high plasma protein binding (~85%), which allows for sustained therapeutic concentrations in tissues. The drug demonstrates excellent tissue penetration, including skin structures, synovial fluid, bone tissue, and macrophages, making it effective in treating complex infections. Its pharmacokinetic properties enable less frequent dosing while maintaining potent activity against Gram-positive pathogens.

These features make oritavancin a convenient option for outpatient therapy, particularly in populations where adherence may be challenging or access to healthcare is limited. It is suitable for prolonged courses in infections such as osteoarticular infections, endocarditis, and other deep-seated Gram-positive infections. Oritavancin should be administered under specialist supervision to ensure optimal efficacy and patient safety.